Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Opal

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Journal of Biotechnology|March 27, 2016
A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapyJohn R North, Shunsuke Takenaka, Annett Rozek, et al.
Critical Care Medicine|June 12, 2004
CD14 receptor occupancy in severe sepsis: results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14)Konrad Reinhart, Thomas Glück, Jack Ligtenberg, et al.
The Journal of Infectious Diseases|July 10, 2004
Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC studyJohn C Marshall, Debra Foster, Jean-Louis Vincent, et al.
The Lancet. Infectious Diseases|May 2, 2015
Sepsis: a roadmap for future researchJonathan Cohen, Jean-Louis Vincent, Neill K J Adhikari, et al.
JAMA Surgery|April 18, 2014
A Novel Drug for Treatment of Necrotizing Soft-Tissue Infections: A Randomized Clinical TrialEileen M Bulger, Ronald V Maier, Jason Sperry, et al.
Critical Care Medicine|February 6, 2004
Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trialSteven Opal, Pierre-Francois Laterre, Edward Abraham, et al.
American Journal of Respiratory and Critical Care Medicine|February 8, 2011
Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trialRichard G Wunderink, Pierre-François Laterre, Bruno Francois, et al.
JAMA|July 10, 2003
Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trialEdward Abraham, Konrad Reinhart, Steven Opal, et al.
Journal of Intensive Care|March 5, 2019
Physician agreement on the diagnosis of sepsis in the intensive care unit: estimation of concordance and analysis of underlying factors in a multicenter cohortBert K Lopansri, Russell R Miller Iii, John P Burke, et al.
Journal of Clinical Medicine|April 9, 2024
Validation of SeptiCyte RAPID to Discriminate Sepsis from Non-Infectious Systemic InflammationRobert Balk, Annette M Esper, Greg S Martin, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Journal of Biotechnology|March 27, 2016
A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapyJohn R North, Shunsuke Takenaka, Annett Rozek, et al.
Critical Care Medicine|June 12, 2004
CD14 receptor occupancy in severe sepsis: results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14)Konrad Reinhart, Thomas Glück, Jack Ligtenberg, et al.
The Journal of Infectious Diseases|July 10, 2004
Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC studyJohn C Marshall, Debra Foster, Jean-Louis Vincent, et al.
The Lancet. Infectious Diseases|May 2, 2015
Sepsis: a roadmap for future researchJonathan Cohen, Jean-Louis Vincent, Neill K J Adhikari, et al.
JAMA Surgery|April 18, 2014
A Novel Drug for Treatment of Necrotizing Soft-Tissue Infections: A Randomized Clinical TrialEileen M Bulger, Ronald V Maier, Jason Sperry, et al.
Critical Care Medicine|February 6, 2004
Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trialSteven Opal, Pierre-Francois Laterre, Edward Abraham, et al.
American Journal of Respiratory and Critical Care Medicine|February 8, 2011
Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trialRichard G Wunderink, Pierre-François Laterre, Bruno Francois, et al.
JAMA|July 10, 2003
Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trialEdward Abraham, Konrad Reinhart, Steven Opal, et al.
Journal of Intensive Care|March 5, 2019
Physician agreement on the diagnosis of sepsis in the intensive care unit: estimation of concordance and analysis of underlying factors in a multicenter cohortBert K Lopansri, Russell R Miller Iii, John P Burke, et al.
Journal of Clinical Medicine|April 9, 2024
Validation of SeptiCyte RAPID to Discriminate Sepsis from Non-Infectious Systemic InflammationRobert Balk, Annette M Esper, Greg S Martin, et al.
Pageof 4